Valuation: Mendus AB

Market Cap 428M 45.35M 38.83M 36.21M 33.32M 62.63M 4.34B 63.69M 168M 2.18B 170M 167M 7.23B P/E 2026 *
-4.44x
P/E 2027 * -5.77x
Enterprise Value 106M 11.28M 9.66M 9M 8.29M 15.57M 1.08B 15.84M 41.67M 542M 42.34M 41.42M 1.8B EV / Sales 2026 *
17.8x
EV / Sales 2027 * 1.54x
Free-Float
34.33%
Yield 2026 *
-
Yield 2027 * -
1 day-1.47%
1 week+3.55%
Current month-3.31%
1 month+11.83%
3 months+18.97%
6 months+36.11%
Current year+19.82%
1 week 6.57
Extreme 6.57
7.5
1 month 6
Extreme 6
7.5
Current year 3.86
Extreme 3.86
7.5
1 year 3.86
Extreme 3.86
9.37
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/2/22 Buy

Chief Technology Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%+3.55%-12.86%+0.30% 45.53M
+2.37%+0.66%+4.21%+22.74% 48.63B
-0.62%+4.43%+488.92%+624.71% 46.3B
+2.09%+4.90%+18.02%+95.21% 41.97B
+3.85%+2.23%+29.47%+16.50% 39.51B
-0.72%-7.79%+17.87%+47.98% 31.75B
+3.04%+0.46%+31.40%+143.62% 16.48B
+4.33%+1.98% - - 16.34B
+1.44%+1.09%+4.93%+31.00% 14B
+3.87%+2.84%+84.74%+45.80% 13.33B
Average +1.27%-0.03%+74.08%+114.21% 26.83B
Weighted average by Cap. +1.58%-0.05%+107.31%+157.18%

Financials

2026 *2027 *
Net sales 5.97M 633K 542K 505K 465K 874K 60.58M 889K 2.34M 30.4M 2.38M 2.32M 101M 150M 15.87M 13.59M 12.67M 11.66M 21.92M 1.52B 22.29M 58.65M 762M 59.59M 58.31M 2.53B
Net income -150M -15.93M -13.64M -12.71M -11.7M -22M -1.52B -22.37M -58.85M -765M -59.8M -58.5M -2.54B -66.57M -7.06M -6.04M -5.64M -5.19M -9.75M -676M -9.91M -26.08M -339M -26.51M -25.93M -1.13B
Net Debt -321M -34.08M -29.18M -27.2M -25.04M -47.06M -3.26B -47.85M -126M -1.64B -128M -125M -5.43B -197M -20.89M -17.89M -16.68M -15.35M -28.86M -2B -29.34M -77.2M -1B -78.44M -76.75M -3.33B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
19/08/26 SEK 6.710 -1.47% 66,587
18/08/26 SEK 6.810 -1.73% 16,127
17/08/26 SEK 6.930 +0.43% 11,257
14/08/26 SEK 6.900 +2.53% 26,075
13/08/26 SEK 6.730 +1.20% 21,041
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.710SEK
Average target price
33.00SEK
Spread / Average Target
+391.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock